SAN FRANCISCO (AP) _ FibroGen Inc. (FGEN) on Tuesday reported a loss of $23.4 million in its second quarter.

The San Francisco-based company said it had a loss of 28 cents per share.

The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 58 cents per share.

The biotech drug developer posted revenue of $44 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $28.7 million.

FibroGen shares have climbed 33 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $62.95, a rise of 88 percent in the last 12 months.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on FGEN at

blog comments powered by Disqus